Select Publications
Journal articles
2010, 'Erratum: Microtubules and resistance to tubulin-binding agents (Nature Reviews Cancer)', Nature Reviews Cancer, 10, pp. 309, http://dx.doi.org/10.1038/nrc2819
,2010, 'Microtubules and resistance to tubulin-binding agents', NATURE REVIEWS CANCER, 10, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000275932700015&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2010, 'Microtubules and resistance to tubulin-binding agents', Nature Reviews Cancer, http://dx.doi.org/10.1038/nrc2830
,2010, 'Anti-fouling magnetic nanoparticles for siRNA delivery', Journal of Materials Chemistry, 20, pp. 255 - 265, http://dx.doi.org/10.1039/b914063h
,2010, 'beta III-Tubulin Is a Multifunctional Protein Involved in Drug Sensitivity and Tumorigenesis in Non-Small Cell Lung Cancer', Cancer research, 70, pp. 4995 - 5003, http://dx.doi.org/10.1158/0008-5472.CAN-09-4487
,2010, 'Block Co-polymer Nanoparticles with Degradable Cross-Linked Core and Low-Molecular-Weight PEG Corona for Anti-tumour Drug Delivery', Journal of Biomaterials Science - Polymer Edition, 22, pp. 1001 - 1022, http://dx.doi.org/10.1163/092050610X497872
,2010, 'ENMD-1198, a New Analogue of 2-Methoxyestradiol, Displays Both Antiangiogenic and Vascular-Disrupting Properties', Molecular Cancer Therapeutics, 9, pp. 1408 - 1418, http://dx.doi.org/10.1158/1535-7163.MCT-09-0894
,2010, 'LIM-kinase 2, a regulator of actin dynamics, is involved in mitotic spindle integrity and sensitivity to microtubule-destabilizing drugs', Oncogene, 29, pp. 597 - 607, http://dx.doi.org/10.1038/onc.2009.367
,2010, 'Metronomic chemotherapy: new rationale for new directions', Nature Reviews Clinical Oncology, 7, pp. 455 - 465, http://dx.doi.org/10.1038/nrclinonc.2010.82
,2010, 'Microtubule Dynamics, Mitotic Arrest, and Apoptosis: Drug-Induced Differential Effects of beta III-Tubulin', Molecular Cancer Therapeutics, 9, pp. 1339 - 1348, http://dx.doi.org/10.1158/1535-7163.MCT-09-0679
,2010, 'Microtubules and resistance to tubulin-binding agents', Nature Reviews Cancer, 10, pp. 194 - 204, http://dx.doi.org/10.1038/nrc2803
,2010, 'TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells', Oncogene, 29, pp. 6172 - 6183, http://dx.doi.org/10.1038/onc.2010.340
,2009, 'The cyclin-dependent kinase inhibitor, p21WAF1, promotes angiogenesis by repressing gene transcription of thioredoxin-binding protein 2 in cancer cells', Carcinogenesis, 30, pp. 1865 - 1871, http://dx.doi.org/10.1093/carcin/bgp225
,2009, 'The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylation', Cancer Letters, 277, pp. 82 - 90, http://dx.doi.org/10.1016/j.canlet.2008.11.030
,2008, 'Potential Mechanisms of Resistance to Microtubule Inhibitors', Seminars in Oncology, 35, http://dx.doi.org/10.1053/j.seminoncol.2008.01.006
,2008, 'A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts', Journal of Pharmacology and Experimental Therapeutics, 324, pp. 434 - 442, http://dx.doi.org/10.1124/jpet.107.128926
,2008, 'Acid-labile core cross-linked micelles for pH-triggered release of antitumor drugs.', Biomacromolecules, 9, pp. 1826 - 1836, http://dx.doi.org/10.1021/bm800043n
,2008, 'Class I beta-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions', Molecular Cancer Therapeutics, 7, pp. 3150 - 3159
,2008, 'Integrative analysis of RUNX1 downstream pathways and target genes.', BMC Genomics, 8, pp. 363
,2008, 'Microtubules: A dynamic target in cancer therapy', IUBMB Life, 60, pp. 165 - 170, http://dx.doi.org/10.1002/iub.25
,2008, 'Perceptions in health and medical research careers: the Australian Society for Medical Research Workforce Survey', Medical Journal of Australia, 188, pp. 520 - 524
,2008, 'Tubulin-Targeted Drug Action: Functional Significance of Class II and Class IVb beta-Tubulin in Vinca Alkaloid Sensitivity', Cancer research, 68, pp. 9817 - 9824
,2007, 'Tubulin/microtubule system as an anti-cancer drug target', Current Cancer Drug Targets, 7, pp. 696, http://dx.doi.org/10.2174/156800907783220444
,2007, 'A pedigree with autosomal dominant thrombocytopenia, red cell macrocytosis, and an occurrence of t(12:21) positive pre-B acute lymphoblastic leukemia', Blood Cells Molecules and Diseases, 39, pp. 107 - 114
,2007, 'Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non-small cell lung cancer', Cancer research, 67, pp. 9356 - 9363
,2007, 'Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of Beta-tubulins', International Journal of Cancer, 120, pp. 2078 - 2085
,2007, 'The cytoskeleton as a therapeutic target in childhood acute leukemia: obstacles and opportunities', Current Drug Targets, 8, pp. 739 - 749
,2006, 'A novel plant toxin, persin, with in vivo activity in the mammary gland, induces Bim-dependent apoptosis in human breast cancer cells', Molecular Cancer Therapeutics, 5, pp. 2300 - 2309
,2006, 'Acid-Cleavable polymeric core-shell particles for delivery of hydrophoblic drugs', Journal of Controlled Release, 115, pp. 197 - 207
,2006, 'Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia', Journal of the National Cancer Institute, 98, pp. 1363 - 1374
,2006, 'Discovering novel strategies for antimicrotubule cytotoxic therapy', EJC Supplements, 4, pp. 3 - 9
,2006, 'Proteomic anlaysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia - an in vivo study', Proteomics, 6, pp. 1681 - 1694
,2006, 'The estrogen-responsive B box protein is a novel regulator of the retinoid signal', The Journal of Biological Chemistry, 281, pp. 18246 - 18256
,2005, 'Improving the targeting of tubulin-binding agents: lessons from drug resistance studies', Current Pharmaceutical Design, 11, pp. 1719 - 1733
,2005, 'Improving the targeting of tubulin-binding agents: lessons from drug resistance studies.', Current Pharmaceutical Design, 11, pp. 1719 - 1733
,2005, 'Proteomics and disease: opportunities and challenges', Medical Journal of Australia, 182, pp. 575 - 579
,2005, 'Tissue-specific tropomyosin isoform composition.', Histochemical Journal, 53, pp. 557 - 570, http://dx.doi.org/10.1369/jhc.4A6505.2005
,2004, 'Neuronal-associated microtubule proteins class III B-tubulin and MAP2c in neuroblastoma: Role in resistance to microtubule-targeted drugs.', Molecular Cancer Therapeutics, 3, pp. 1137 - 1146
,2003, 'Drug Resistance Mechanisms in Cancer Cells: A Proteomics Perspective', Current Opinion in Molecular Therapeutics, 5, pp. 258 - 265
,2003, 'Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma', Journal of National Cancer Institute, 95, pp. 1394 - 1403
,2003, 'Growth inhibitory retinoid effects after recruitment of retinoid X receptor B to the retinoic acid receptor B promoter', International Journal of Cancer, 105, pp. 856 - 867
,2003, 'Microtubule alterations and mutations induced by desoxyepothilone B: Implications for drug-target', Chemistry and biology, 10, pp. 597 - 607
,2003, 'Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukaemia reveals novel cytoskeletal alternations', The Journal of Biological Chemistry, 278, pp. 45082 - 45093
,2002, 'Anticancer therapy with novel tubulin-interacting drugs', Drug Resistance Updates, 4, pp. 392 - 401
,2002, 'Microtubule alterations and resostance to tubulin-binding agents', International Journal of Oncology, 21, pp. 621 - 628
,2001, 'Markedly diminished drug-resistance including properties of vinflunine (20`, 20`- difluro- 3`, 4` - dihydrovinorelbine) relative tovinorelbine, identified in murine and human tumour cells in vivo and in vitro, with clinical implications', Cancer Chemotherapy and Pharmacology, pp. 62 - 70
,2001, 'Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukemia cells', Cancer research, pp. 5803 - 5809
,2001, 'The role of beta-tubulin isotypes in resistance to antimitotic drugs', Biochimica et Biophysica ACTA, 1471, pp. 1 - 9
,2000, 'Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumour cells', Cell death and differentiation, pp. 102 - 111
,1999, 'Altered expression of the MYCN Oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells', Oncogene, 18, pp. 2777 - 2782
,